1.13
price up icon3.67%   0.04
pre-market  プレマーケット:  1.12   -0.010   -0.88%
loading
前日終値:
$1.09
開ける:
$1.12
24時間の取引高:
3.65M
Relative Volume:
0.37
時価総額:
$235.77M
収益:
$176.23M
当期純損益:
$-257.83M
株価収益率:
-0.7687
EPS:
-1.47
ネットキャッシュフロー:
$-246.00M
1週間 パフォーマンス:
+10.24%
1か月 パフォーマンス:
-54.25%
6か月 パフォーマンス:
+184.56%
1年 パフォーマンス:
+161.51%
1日の値動き範囲:
Value
$1.07
$1.15
1週間の範囲:
Value
$1.05
$1.15
52週間の値動き範囲:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
名前
Sangamo Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
(510) 970-6000
Name
住所
501 CANAL BLVD., RICHMOND, CA
Name
職員
405
Name
Twitter
@sangamotx
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
SGMO's Discussions on Twitter

SGMO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
1.13 235.77M 176.23M -257.83M -246.00M -1.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 アップグレード Truist Hold → Buy
2024-12-10 繰り返されました H.C. Wainwright Buy
2023-11-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-04-28 ダウングレード BofA Securities Neutral → Underperform
2023-02-27 アップグレード Wedbush Neutral → Outperform
2023-01-06 ダウングレード BofA Securities Buy → Neutral
2022-06-13 再開されました Wedbush Neutral
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-01-07 再開されました Guggenheim Neutral
2021-01-06 開始されました Stifel Hold
2020-12-16 再開されました H.C. Wainwright Buy
2020-09-08 開始されました BofA Securities Buy
2020-07-07 開始されました SunTrust Buy
2019-08-26 開始されました H.C. Wainwright Buy
2018-11-14 ダウングレード JP Morgan Overweight → Neutral
2018-11-09 ダウングレード Guggenheim Buy → Neutral
2018-10-10 開始されました Guggenheim Buy
2018-06-20 開始されました BofA/Merrill Buy
2017-11-15 アップグレード Piper Jaffray Neutral → Overweight
2017-06-22 再開されました Jefferies Buy
2016-11-01 ダウングレード Wedbush Outperform → Neutral
2016-10-19 ダウングレード Piper Jaffray Overweight → Neutral
2015-12-04 開始されました Wells Fargo Outperform
2015-10-23 再開されました Jefferies Buy
2013-05-03 開始されました BioLogic Equity Research Sell
2011-02-23 繰り返されました JMP Securities Mkt Outperform
2010-07-29 繰り返されました Wedbush Outperform
2009-10-19 開始されました Brean Murray Sell
2009-10-07 繰り返されました Leerink Swann Outperform
2009-08-25 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Sangamo Therapeutics Inc (SGMO) 最新ニュース

pulisher
Jan 20, 2025

Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN

Jan 20, 2025
pulisher
Jan 16, 2025

Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - News & Insights

Jan 16, 2025
pulisher
Jan 16, 2025

Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq

Jan 16, 2025
pulisher
Jan 15, 2025

Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire

Jan 15, 2025
pulisher
Jan 14, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire

Jan 14, 2025
pulisher
Jan 12, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire

Jan 12, 2025
pulisher
Jan 10, 2025

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire

Jan 10, 2025
pulisher
Jan 10, 2025

Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN

Jan 10, 2025
pulisher
Jan 10, 2025

Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL

Jan 10, 2025
pulisher
Jan 09, 2025

WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com

Jan 09, 2025
pulisher
Jan 09, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire

Jan 09, 2025
pulisher
Jan 08, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - AccessWire

Jan 08, 2025
pulisher
Jan 07, 2025

15 Small-Cap Stocks Poised to Outperform in 2025 - Insider Monkey

Jan 07, 2025
pulisher
Jan 07, 2025

Sangamo to regain rights to hemophilia A gene therapy - Hemophilia News Today

Jan 07, 2025
pulisher
Jan 06, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect - AccessWire

Jan 06, 2025
pulisher
Jan 06, 2025

Hemoglobinopathies Market Projected to Show Strong Growth| - openPR

Jan 06, 2025
pulisher
Jan 05, 2025

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire

Jan 05, 2025
pulisher
Jan 04, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation - AccessWire

Jan 04, 2025
pulisher
Jan 03, 2025

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More - Zacks Investment Research

Jan 03, 2025
pulisher
Jan 02, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - PR Newswire

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership - MSN

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com India

Jan 02, 2025
pulisher
Jan 02, 2025

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com Nigeria

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal - MSN

Jan 02, 2025
pulisher
Jan 02, 2025

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership - MM+M Online

Jan 02, 2025
pulisher
Jan 02, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation - AccessWire

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwright - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer - Contract Pharma

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership - Barron's

Jan 02, 2025
pulisher
Jan 02, 2025

Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact - BioSpace

Jan 02, 2025
pulisher
Jan 02, 2025

Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.

Jan 02, 2025
pulisher
Dec 31, 2024

Sangamo Therapeutics: Left At The Alter (Rating Downgrade) - Seeking Alpha

Dec 31, 2024
pulisher
Dec 31, 2024

Sangamo stock plunges as Pfizer leaves hemophilia partnership - BioWorld Online

Dec 31, 2024
pulisher
Dec 31, 2024

Jefferies Financial Group Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $3.00 - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Options run thin for Sangamo Therapeutics after Pfizer deal crashesSan Francisco Business Times - San Francisco Business Times

Dec 31, 2024
pulisher
Dec 31, 2024

Sangamo Therapeutics Stock Plummets 50% After Pfizer Ends Hemophilia Treatment Partnership - MSN

Dec 31, 2024
pulisher
Dec 31, 2024

9 Analysts Have This To Say About Sangamo Therapeutics - Benzinga

Dec 31, 2024
pulisher
Dec 31, 2024

Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing - MedCity News

Dec 31, 2024
pulisher
Dec 31, 2024

Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends Hemophilia pact - MSN

Dec 31, 2024
pulisher
Dec 31, 2024

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga

Dec 31, 2024
pulisher
Dec 31, 2024

Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemop - GuruFocus.com

Dec 31, 2024
pulisher
Dec 31, 2024

Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact - MarketWatch

Dec 31, 2024

Sangamo Therapeutics Inc (SGMO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):